Sudeep Pharma IPO: ₹895 Cr Issue Opens Nov 21
Sudeep Pharma's ₹895 crore IPO opens November 21-25. Price band ₹563-593 per share. Company manufactures pharmaceutical excipients and speciality ingredients.
Sudeep Pharma's ₹895 crore IPO opens November 21-25. Price band ₹563-593 per share. Company manufactures pharmaceutical excipients and speciality ingredients.
Sudeep Pharma IPO opens November 21 with price band ₹563-593 per share. Company aims to raise ₹95 crore. Learn key dates, financials, and investment details.
Supreme Power Equipment reports stellar H1 FY26 results with 29% revenue growth and 32% net profit increase. Strong performance driven by robust order book and operational excellence.
Remedium Lifecare reports stellar Q2 results with profit nearly doubling to ₹38.62 crore. Revenue surges 22% driven by strong pharmaceutical exports and domestic growth.
Hvax Technologies announces impressive 35% growth in total income for H1 FY26, reaching ₹5.95 crore. The company shows strong financial performance with significant profit improvements.
European weight-loss drug makers surge as investors rotate capital from expensive AI stocks into healthcare. Zealand Pharma leads with a 20% weekly jump. Explore the market dynamics.
Purdue Pharma receives court approval for $7.4 billion opioid settlement after Supreme Court intervention. Sackler family to pay $6.5 billion over 15 years in landmark case.
Federal judge approves Purdue Pharma's bankruptcy plan requiring Sackler family to pay $7 billion and surrender company ownership. Thousands of opioid victims to receive compensation in historic settlement.
Lincoln Pharmaceuticals Ltd announces ambitious plan to achieve Rs 1000 crore revenue within three years through strategic expansion and new product launches. Read more about their growth strategy.
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Tragic boiler explosion at pharmaceutical factory in Gujarat's Bharuch district claims 2 lives, leaves 20 injured. Massive fire brought under control by emergency teams.
India's DCGI orders nationwide inspections of small pharma units as WHO flags toxic cough syrups. MSMEs struggle to meet new Schedule M compliance deadline of January 2026.
DCGI directs state authorities to enforce strict GMP compliance by December 31, 2025. Delhi, Himachal Pradesh, Uttarakhand already taking action against non-compliant manufacturers.
India's drug regulator DCGI mandates global manufacturing standards for all pharma companies by January 2026. State regulators ordered to begin inspections immediately. Read about the strict compliance requirements.
Sun Pharma investors await Q2 FY26 results with cautious optimism as US tariff clarity emerges. Discover how import duties and market dynamics could impact India's pharmaceutical giant.
Indian pharmaceutical companies are reporting exceptional earnings driven by US generic drug sales, leading to major fundraising initiatives for expansion into medtech and wellness sectors.
British-Swedish pharma giant AstraZeneca reports blockbuster Q3 results with profits surging 77% to $2.53 billion, driven by robust cancer drug sales and strategic US market expansion.
Piramal Pharma anticipates significant growth as US biopharma funding shows recovery signs, with CDMO business poised for major expansion.
Premium custom shirt brand Bombay Shirt Company announces major expansion across Delhi-NCR with new stores and experience centers, revolutionizing personalized fashion in North India.
India's corporate regulatory framework undergoes significant transformation with revamped Company Law Administration launching in January 2024, promising streamlined services and robust oversight for businesses.
Delhivery shows significant financial improvement with reduced Q2 losses and strategic leadership changes as Vivek Pabari prepares to take over as CFO.
Solara Active Pharma Sciences faces challenging quarter with ₹10 crore net loss despite revenue growth. Discover the operational challenges and management's recovery strategy.
India's pharmaceutical giant Sun Pharma reports steady Q2 growth with 9% revenue increase while navigating US market challenges. Key insights from their latest earnings report.
Discover why Navin Fluorine International shares skyrocketed 22% in just three trading sessions. Expert analysis reveals the key drivers behind this chemical sector powerhouse's impressive rally and what investors should watch next.
Unlock the secrets of India's share buyback tax regime. Learn how it impacts investors and companies, tax implications, and strategic considerations for maximum returns.
Market eyes Wednesday's Q2 earnings bonanza as pharma giant Sun Pharma, Grasim Industries, and FMCG major Britannia declare results. Get complete analysis and investor expectations.
Indian company promoters are aggressively buying small-cap stocks, signaling strong belief in their companies' growth prospects amid market expansion and investment opportunities.
Discover how RegisterKaro is transforming the business landscape by making Private Limited company registration completely paperless, fast, and hassle-free for Indian entrepreneurs.
Religare Broking's Ajit Mishra reveals 3 promising stocks for short-term gains. Discover technical analysis and price targets for Grasim, Aurobindo Pharma, and City Union Bank in this exclusive market insight.
Get expert stock market insights from Jigar Patel of Anand Rathi as he reveals why Oil India, Aurobindo Pharma, and Latent View Analytics present compelling short-term opportunities for Indian investors.